Combined treatment with CDK7 and lapatinib greatly inhibited both HER2 activation and RNA Pol II phosphorylation and enhanced tumor cell apoptosis as assessed by increased levels of the active form of PARP (Fig. 5d). Here, ERBB2 is linked to neoplasm.